Free tool
Drug Trial Radar: Ophthalmology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
19
Not yet recruiting, industry sponsors, Ophthalmology, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed555
19 trials
Showing 1 to 19, recently updated first.
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Macular Edema After Retinal Vein Occlusion (MK-8748-006)Pivotal-lookingNot yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07951515 · 1,188 participants (planned) · Start Dec 21, 2026 · Primary completion Nov 19, 2029
Drug: MK-8748; Aflibercept · For: Retinal Vein Occlusion; Macular Edema
- A Clinical Trial to Evaluate the Efficacy and Safety of Bevemipretide Ophthalmic Topical Solution in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)Pivotal-lookingNot yet recruiting
Mighty Therapeutics Inc.Industry
NCT07927010 · 300 participants (planned) · Start Nov 2026 · Primary completion Mar 2029
Drug: 1 % Bevemipretide; 2% Bevemipretide · For: Dry AMD; Age-Related Macular Degeneration (AMD)
- A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular DegenerationPivotal-lookingNot yet recruiting
Everest Medicines (China) Co.,Ltd.Industry
NCT07798375 · 244 participants (planned) · Start Nov 2026 · Primary completion Jul 2028
Drug: VIS-101 6.0mg Low concentration; VIS-101 6.0mg High concentration and 2 more · For: Neovascular Age Related Macular Degeneration(nAMD)
- Study of CU06-1004 in Patients With Daibetic Macular EdemaPivotal-lookingNot yet recruiting
Curacle Co., Ltd.Industry
NCT07459829 · 156 participants (planned) · Start Dec 1, 2026 · Primary completion Jan 1, 2028
Drug: CU06-1004; Placebo Control · For: DME; Diabetic Macular Edema; Diabetic Macular Edema (DME)
- A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's DiseasePivotal-lookingNot yet recruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT07836660 · 198 participants (planned) · Start Oct 15, 2026 · Primary completion Nov 1, 2027
Drug: Part A - Placebo for IBI355; Part B -Telitacicept and 2 more · For: Sjögren's Disease
Sites: Hefei, China
Filamon LTDIndustry
NCT07766473 · 24 participants (planned) · Start Sep 2026 · Primary completion Mar 2027
Drug: BETA-TT8 ophthalmic gel 3.8% w/v · For: Neovascular (Wet) Age-Related Macular Degeneration
Sites: Gosford, Australia; Sydney, Australia; Westmead, Australia · 4 sites in all
- ONO-4915 in Patients With Primary Sjogren's DiseaseNot yet recruiting
Ono Pharmaceutical Co., Ltd.Industry
NCT07823790 · 60 participants (planned) · Start Oct 2026 · Primary completion Feb 2029
Drug: ONO-4915; Placebo · For: Sjogren's Disease
- Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A GeneNot yet recruiting
Laboratoires TheaIndustry
NCT07796646 · 81 participants (planned) · Start Oct 5, 2026 · Primary completion Feb 28, 2030
Drug: Intravitreal Injection of Ultevursen · For: Retinitis Pigmentosa (RP); Usher Syndrome Type 2; Deaf Blind and 4 more
- An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic AtrophyNot yet recruiting
EyevensysIndustry
NCT07705568 · 24 participants (planned) · Start Sep 2026 · Primary completion Jun 2028
Drug: PST-611 · For: Geographic Atrophy; Age - Related Macular Degeneration (AMD)
Sites: Grenoble, France; Paris, France · 3 sites in all
- A Phase 2 Study of RCI001 Ophthalmic Solution in Participants With Dry Eye DiseasePivotal-lookingNot yet recruiting
RudacureIndustry
NCT07625124 · 200 participants (planned) · Start Sep 1, 2027 · Primary completion Jun 30, 2028
Drug: RCI001 Ophthalmic Solution; Placebo Ophthalmic Solution · For: Dry Eye
- Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular DegenerationNot yet recruiting
SCAI TherapeuticsIndustry
NCT07607561 · 50 participants (planned) · Start Nov 1, 2026 · Primary completion Aug 31, 2027
Drug: SCAI-005 0.04% 2drops TID; SCAI-005 0.08% 2drops TID and 1 more · For: wetAMD; Age Related Macular Degeneration
- This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B.Pivotal-lookingNot yet recruiting
Shenzhen Oculgen Biomedical Technology Co., Ltd.Industry
NCT07520318 · 255 participants (planned) · Start Apr 17, 2026 · Primary completion Feb 1, 2029
Drug: bispecific anti-VEGF and anti-complement · For: Adults With Neovascular Age-related Macular Degeneration
- Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/IIPivotal-lookingNot yet recruiting
PT. Prodia Stem Cell IndonesiaIndustry
NCT05909488 · 30 participants (planned) · Start May 2026 · Primary completion Jul 2027
Drug: 1.5 x 10^6 UC-MSC + CM; 5 x 10^6 UC-MSC + CM · For: Retinitis Pigmentosa
Sites: Yogyakarta, Indonesia
- Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMDNot yet recruiting
Evergreen Therapeutics, Inc.Industry
NCT05170048 · 90 participants (planned) · Start Jun 2026 · Primary completion Jun 2028
Drug: EG-301 · For: Non-Exudative (Dry) Age-related Macular Degeneration (dAMD)
- A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye DiseaseNot yet recruiting
BRIM Biotechnology Inc.Industry
NCT07078955 · 99 participants (planned) · Start Dec 2025 · Primary completion Nov 2026
Drug: BRM421 Ophthalmic Solution, 0.03%; Artificial Tear and 1 more · For: Dry Eye Disease (DED); Keratoconjunctivitis Sicca
Sites: New Taipei City, Taiwan
- A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME PatientsNot yet recruiting
SciNeuroIndustry
NCT07199777 · 60 participants (planned) · Start Nov 2025 · Primary completion Nov 2026
Drug: SNP318; Placebo · For: Diabetic Macular Edema; DME
- Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMDNot yet recruiting
Guangzhou Jiayin Biotech LtdIndustry
NCT07178249 · 60 participants (planned) · Start Oct 16, 2025 · Primary completion Feb 28, 2028
Drug: EXG202 injection · For: Wet Age-related Macular Degeneration
- A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry EyePivotal-lookingNot yet recruiting
ORA, Inc.Industry
NCT07068958 · 200 participants (planned) · Start Aug 1, 2025 · Primary completion Nov 1, 2025
Drug: 0.25% RCI001 Ophthalmic Solution; Placebo Ophthalmic Solution (vehicle) · For: Dry Eye Disease (DED)
- Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMDNot yet recruiting
Beijing Anlong Biopharmaceutical Co., Ltd.Industry
NCT06839339 · 40 participants (planned) · Start Feb 18, 2025 · Primary completion Sep 30, 2026
Drug: AL-001; Aflibercept · For: Wet Age-related Macular Degeneration (wAMD)
Sites: Beijing, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.